DRKS00030837
Recruiting
Not Applicable
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local Recurrences - CHANCES
Europäisches Radiochirurgie Centrum München0 sites50 target enrollmentDecember 6, 2022
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- C61
- Sponsor
- Europäisches Radiochirurgie Centrum München
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically confirmed prostate cancer in the past medical history, radiographically verified local recurrence, status post prostatectomy and/or external beam radiotherapy
Exclusion Criteria
- •Lymph node metastases or distant metastases in the past medical history
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Stereotactic body radiotherapy followed by surgical stabilization for patients with painful unstable spinal metastases: First-in-man study according to the IDEAL recommendationsmetastatic spine tumorspinal metastases100059591002747610005944NL-OMON42087niversitair Medisch Centrum Utrecht13
Recruiting
Not Applicable
Potential abscopal effect of stereotactic body radiotherapy on the recurrence of hepatocellular carcinoma: An exploratory observation studyHepatocellular carcinomaJPRN-UMIN000038312ational Hospital Organization Nagasaki Medical Center280
Recruiting
Not Applicable
Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: A randomized trial (BLEND RCT)NL-OMON51812niversitair Medisch Centrum Utrecht100
Withdrawn
Phase 2
ungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomized phase III trialLung CancerNon-small-cell lung cancer10038666NL-OMON40781European Organisation for Research in Treatment of Cancer (EORTC)42
Recruiting
Not Applicable
Dose-optimized stereotactic body radiotherapy for locally advanced or recurrent pancreatic andenocarcinomaC25Malignant neoplasm of pancreasDRKS00027912ordstrahl30